Receptor News and Research

RSS

NIDA supports Omeros' Addiction program

Omeros Corporation today announced that the National Institute on Drug Abuse (NIDA) is providing support for the Company's Addiction program. NIDA will fund substantially all of the costs of a Phase 2 clinical study to be conducted by New York State Psychiatric Institute researchers.

28 Jan 2010

Idera Pharmaceuticals commences IMO-3100 Phase 1 clinical trial for autoimmune diseases

Idera Pharmaceuticals, Inc. today announced initiation of a Phase 1 clinical trial of IMO-3100, an antagonist of Toll-like Receptor (TLR) 7 and TLR9.

28 Jan 2010

Blocking action of key protein boosts immune 'memory' to prevent or clear viral infection

Researchers at The Scripps Research Institute have discovered a potential new way to stimulate the immune system to prevent or clear a viral infection. By blocking the action of a key protein in the mouse immune system, they were able to boost immune "memory" in those mice-work that may one day help doctors increase the effectiveness of human vaccines designed to prevent viral infections.

28 Jan 2010

Seroquel XR's FDA approval does not change Decision Resources' earlier antipsychotics market forecast

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the recent decision by the U.S. Food and Drug Administration (FDA) to grant approval of AstraZeneca's Seroquel XR for adjunctive treatment of major depressive disorder will not change Decision Resources' market forecast for the indication. As previously forecasted, Seroquel and Seroquel XR will garner nearly one quarter of antipsychotics sales as adjunctive treatments for major depressive disorder in 2013 in the world's major pharmaceutical markets.

28 Jan 2010

IRSF announces first 2010 ANGEL Grant for testing potential Rett Syndrome therapies

Today, the International Rett Syndrome Foundation (IRSF) announced that it will commit $446,000 in 2010 to fund a large translational research program to test potential therapeutics for Rett Syndrome in mouse models of the disease. The funds will be awarded through the IRSF's new Advanced Neurotherapeutic Grant of Excellence (ANGEL) mechanism which seeks to provide funds for translational research. IRSF is the world's largest private source of Rett syndrome research funding, supporting nearly $21 million in research programs to date. This is the first ANGEL Grant supported by IRSF in 2010.

28 Jan 2010

Case Western Reserve University School of Medicine awarded 6 DOD CDMRP grants for medical research

Case Western Reserve University School of Medicine has been awarded six Department of Defense (DOD) Congressionally Directed Medical Research Programs (CDMRP) grants for innovative medical research. The grants, totaling nearly $2.8 million, will advance research in the field of breast cancer.

28 Jan 2010

Good bacteria may help counteract negative effects of antibiotics in humans

Scientists have long pondered the seeming contradiction that taking broad-spectrum antibiotics over a long period of time can lead to severe secondary bacterial infections. Now researchers from the University of Pennsylvania School of Medicine may have figured out why.

27 Jan 2010

Two new studies further the understanding of molecular steps in PLC cascade

Two new studies by researchers at the University of Washington further our understanding of the molecular steps in the PLC cascade, a G protein-coupled receptor signaling mechanism that underlies a wide variety of cellular processes, including egg fertilization, hormone secretion, and the regulation of certain potassium channels.

27 Jan 2010

USAN approves generic name "ulimorelin" for Tranzyme Pharma's TZP-101

Tranzyme Pharma today announced that the United States Adopted Name Council (USAN) has approved the generic name “ulimorelin” for Tranzyme’s novel, late-stage, prokinetic agent TZP-101. Ulimorelin, if approved, is expected to be a first-in-class drug for the treatment of gastrointestinal (GI) dysmotility indications in acute care (hospital-based) settings.

27 Jan 2010

Research could help develop sophisticated treatments for Type I diabetes

New research that significantly improves our understanding of how insulin interacts with cells in the human body is published today.

27 Jan 2010

FDA approves Victoza to treat type 2 diabetes in some adults

The U.S. Food and Drug Administration today approved Victoza (liraglutide), a once-daily injection to treat type 2 diabetes in some adults.

27 Jan 2010

New technology may allow scientists to monitor real time activity of protein network

A new assay capable of examining hundreds of proteins at once and enabling new experiments that could dramatically change our understanding of cancer and other diseases has been invented by a team of University of Chicago scientists.

24 Jan 2010

ACS Chemical Biology report supports zebrafish for drug development

By combining the tools of medicinal chemistry and zebrafish biology, a team of Vanderbilt investigators has identified compounds that may offer therapeutic leads for bone-related diseases and cancer.

22 Jan 2010

Norepinephrine responses to bucindolol influenced by alpha-2C adrenergic receptor genotype

ARCA biopharma, Inc., a biopharmaceutical company developing genetically targeted therapies for heart failure and other cardiovascular disease, today announced that the paper “An alpha-2C-Adrenergic Receptor Polymorphism Alters the Norepinephrine Lowering Effects and Therapeutic Response of the Beta Blocker Bucindolol in Chronic Heart Failure” was published in the January 2010 edition of the peer-reviewed journal Circulation: Heart Failure (http://circheartfailure.ahajournals.org).

22 Jan 2010

Researchers identify new therapeutic approach for stroke treatment

For the first time, research led by Youming Lu, PhD, MD, Professor of Neurology and Neuroscience at LSU Health Sciences Center New Orleans School of Medicine, has identified a novel mechanism that may trigger brain damage during stroke and identified a therapeutic approach to block it.

22 Jan 2010

Findings may provide new insights into diabetes; suggest novel targets for drug intervention

The neuropeptide corticotropin-releasing factor (CRF) makes cameo appearances throughout the body, but its leading role is as the opening act in the stress response, jump-starting the process along the hypothalamus-pituitary-adrenal (HPA) axis. Researchers at the Salk Institute for Biological Studies have found that CRF also plays a part in the pancreas, where it increases insulin secretion and promotes the division of the insulin-producing beta cells.

22 Jan 2010

Findings may aid in developing therapeutic drugs for stroke and other neurodegenerative diseases

Biomedical scientists from the University of Central Florida and Louisiana State University have identified a way to block a "cell death signal" that they believe triggers brain damage during strokes.

22 Jan 2010

Mice study shows obesity can increase risk of developing liver cancer

Obesity comes with plenty of health risks, but there's one that's perhaps not so well known: an increased risk of developing cancer, and especially certain types of cancer like liver cancer. Now, a group of researchers reporting in the January 22nd issue of the journal Cell, a Cell Press publication, have confirmed in mice that obesity does indeed act as a "bona fide tumor promoter." They also have good evidence to explain how that happens.

22 Jan 2010

FDA accepts ACT Biotech's ACTB1003 IND

ACT Biotech Inc., a privately held biotechnology company developing a portfolio of oral kinase inhibitors as anti-cancer drugs, today announced the acceptance of the Investigational New Drug (IND) application for ACTB1003 by the US Food and Drug Administration (FDA). The company has now assembled a complete preclinical package, including manufacturing and toxicology studies, allowing ACTB1003 to enter a clinical trial.

22 Jan 2010

China Pharma Holdings announces completion of clinical trials for Candesartan

China Pharma Holdings, Inc., which develops, manufactures, and markets specialty pharmaceutical products in China, today announced that the Company has completed clinical trials for Candesartan, an anti-hypertension drug, and submitted the generic drug production application to the SFDA.

21 Jan 2010

Receptor News and Research

NIDA supports Omeros' Addiction program

Idera Pharmaceuticals commences IMO-3100 Phase 1 clinical trial for autoimmune diseases

Blocking action of key protein boosts immune 'memory' to prevent or clear viral infection

Seroquel XR's FDA approval does not change Decision Resources' earlier antipsychotics market forecast

IRSF announces first 2010 ANGEL Grant for testing potential Rett Syndrome therapies

Case Western Reserve University School of Medicine awarded 6 DOD CDMRP grants for medical research

Good bacteria may help counteract negative effects of antibiotics in humans

Two new studies further the understanding of molecular steps in PLC cascade

USAN approves generic name "ulimorelin" for Tranzyme Pharma's TZP-101

Research could help develop sophisticated treatments for Type I diabetes

FDA approves Victoza to treat type 2 diabetes in some adults

New technology may allow scientists to monitor real time activity of protein network

ACS Chemical Biology report supports zebrafish for drug development

Norepinephrine responses to bucindolol influenced by alpha-2C adrenergic receptor genotype

Researchers identify new therapeutic approach for stroke treatment

Findings may provide new insights into diabetes; suggest novel targets for drug intervention

Findings may aid in developing therapeutic drugs for stroke and other neurodegenerative diseases

Mice study shows obesity can increase risk of developing liver cancer

FDA accepts ACT Biotech's ACTB1003 IND

China Pharma Holdings announces completion of clinical trials for Candesartan

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News